A Study to Assess the Safety, Tolerability and Pharmacokinetics (PK) of Xanomeline With Trospium Chloride Versus KarXT in Healthy Adult and Elderly Participants of Japanese Ethnicity and to Assess the Effect of Omeprazole on the PK of Xanomeline With Trospium Chloride in Healthy Adult Participants

NCT06605950 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

78

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy Volunteers

Interventions

DRUG: KarXT
DRUG: KarX-EC
DRUG: Placebo
DRUG: Omeprazole

Sponsor

Karuna Therapeutics, Inc., a Bristol Myers Squibb company